Biotech company Alvotech S.A. (NASDAQ:ALVO) announced on Tuesday an agreement with German pharmaceutical company STADA Arzneimittel AG (FWB:SAZ) to form a broader biosimilar partnership.
Under the new agreement STADA gets marketing rights for Alvotech's AVT03, a clinical-stage biosimilar candidate referencing Prolia/Xgeva (denosumab), in Europe and parts of Central Asia and the Middle East. This builds on their existing alliance for biosimilars.
Alvotech will develop and manufacture AVT03, targeting osteoporosis and cancer-related bone loss. Upon approval, STADA will commercialise it in specified territories.
The agreement also expands STADA's commercial rights to existing Alvotech biosimilars in Central Asia, while Alvotech will regain commercial rights from STADA to AVT06, a proposed biosimilar to Eylea (aflibercept).
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient